<DOC>
	<DOCNO>NCT01728051</DOCNO>
	<brief_summary>The safety efficacy CS-PHP-melphalan evaluate phase 3 trial conduct patient population well use melphalan dose propose study . This expand access protocol provide experimental alternative treatment option physicians patient Delcath CS-PHP System receive market approval .</brief_summary>
	<brief_title>Expanded Access Study Melphalan With Delcath CS-PHP System Patients With Ocular/Cutaneous Melanoma Mets Liver</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>1 . Histologically proven ocular/cutaneous melanoma liverdominant unresectable metastatic disease , define limited extrahepatic disease hepatic involvement would , Investigator 's opinion , result morbidity eventual mortality . Limited extrahepatic disease consider acceptable include : 4 pulmonary nodule , &lt; 1cm diameter retroperitoneal lymph node &lt; 1cm diameter resectable skin subcutaneous metastasis asymptomatic bone metastasis , , palliate external beam radiation therapy solitary metastasis site resect limited morbidity control radiation 2 . ≥1 measurable hepatic lesion per RECIST 1.1 3 . Vasculature compatible insertion CSPHP catheter , per baseline abdominal MRA 4 . ECOG PS 02 1 . Chemotherapy , radiotherapy , biologic therapy malignancy ≤1 month prior 1st CSPHPmelphalan infusion 2 . Extensive prior radiotherapy , define treatment ≥50 % marrowcontaining bone 3 . Immunosuppressive drug cyclosporine , tacrolimus , azathioprine , longterm oral glucocorticoid take currently ≤3 mths prior 1st CSPHPmelphalan infusion 4 . Received investigational product ≤30 day prior 1st CSPHPmelphalan infusion 5 . History orthotopic liver transplantation , untreated gastrinoma ( i.e . gastric acid hypersecretion ) prior Whipple procedure 6 . Not recovered side effect prior therapy ≤ Grade 1 NCI CTCAE 4.03 7 . Child 's B C cirrhosis , clinical evidence portal hypertension 8 . Patients &gt; 50 % liver replace tumor , histologic evidence hepatic dysfunction see laparoscopic liver biopsy 9 . History evidence clinically significant cardiac disease symptomatic arrhythmia , angina/ischemia , coronary artery bypass graft surgery percutaneous transluminal coronary angioplasty , uncontrolled atrial fibrillation , CHF leave ventricular ejection fraction &lt; 40 % , uncontrolled hypertension ( SBP &gt; 190 mmHg DBP &gt; 100 mmHg ) , HR outside normal range 50100 bpm woman 45100 bpm men 10 . History/evidence clinically significant pulmonary cardiac disease incompatible fitness undergo general anesthesia 11 . Uncontrolled diabetes mellitus hypo/hyperthyroidism 12 . Active uncontrolled infection 13 . History bleed disorder know unresolved venous shunt 14 . Requirement ongoing chronic anticoagulation 15 . Evidence intracranial abnormality result risk bleed anticoagulation 16 . History alcohol drug abuse ≤6 mths 17 . Other malignancy within 3 yrs enrollment exception curatively treat basal squamous cell carcinoma skin , curatively treated cervical , breast carcinoma situ prostate cancer 18 . History hypersensitivity : melphalan component ; iodine contrast control premedication antihistamine steroid ; latex 19 . Known hypersensitivity heparin presence heparininduced thrombocytopenia antibody 20 . Inadequate hematological renal function indicate follow : Platelets &lt; 100,000/mm3 Hb ≤10 g/dL Neutrophils &lt; 2,000/mm3 S Creat &gt; 1.5 mg/dL measure creatinine clearance &lt; 60 mL/min/1.73 m2 21 . Inadequate liver function indicate follow : Tbili ≥3.0 mg/dL INR &gt; 1.5 AST/ALT &gt; 5xULN 22 . Pregnant nursing 23 . Positive pregnancy test subject childbearing potential ≤7 day prior first CSPHPmelphalan infusion 24 . Women premenopausal ( i.e . menstrual period ≤12 month ) unwilling unable undergo hormonal suppression avoid menstruation treatment 25 . Sexually active female childbearing potential sexually active male partner reproductive potential unwilling unable use contraception screen least 30 day last administration CSPHPmelphalan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>